Skip to main content
Premium Trial:

Request an Annual Quote

Astute Receives 510(k) Clearance for NephroCheck AKI Test

NEW YORK (GenomeWeb) – Astute Medical said today that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.

The company said it plans to launch US sales of the test in coming weeks through its strategic partner Ortho Clinical Diagnostics, the exclusive sales agent for Nephrocheck.

"The availability of biomarkers for AKI risk assessment can play a pivotal role in evolving practice from a 'wait and see' era to a 'let's prevent and treat it domain' Mayo Clinic nephrologist Kianoush Kashani said in a statement. "Clinicians will be able to integrate the test with clinical information to improve decision making, which aligns with the goal of offering better preventive care and earlier action."

According to Astute, AKI is a significant contributor to hospital deaths and increased healthcare costs, often afflicting the sickest patients, including those with sepsis and who have undergone major surgery.

NeproCheck measures the presence of two proteins – insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) – in urine, allowing clinicians to assess in about 20 minutes the risk of a patient developing AKI in the next 12 hours.

San Diego-based Astute received an EU CE mark for the test and launched European sales in 2012.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.